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gender, ethnicity, marital status, educational attainment, household income, em-
ployment status, insurance possession, body mass index, exercise and smoking
habits, alcohol use, and HIV/AIDS and hepatitis B status as predictors. RESULTS:
Mean age was similar between hepatitis C patients who had ever initiated treat-
ment (51.3 yrs, SD11.39) and thosewho had not (52.0 yrs, SD11.50). Patients who
were married (OR1.43, p.004), in possession of insurance (OR1.56, p.003), or
diagnosed with AIDS or HIV (OR1.60, p.05) were more likely to have initiated
treatment than patients without those characteristics. No other significant differ-
ences were found. CONCLUSIONS: The current findings indicate that lack of insur-
ance and lack of support from a partner are associatedwith lower odds of initiating
treatment for hepatitis C. While speculative, this suggests that lack of social sup-
port and insurance may be barriers to treatment. Patients treated for hepatitis C
may be more informed about their HIV/AIDS status, although conversely, patients
with HIV/AIDS may be more likely to initiate therapy to avoid liver-related immu-
nodeficiency complications. Further investigation is needed to help determine the
direction of causation.
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OBJECTIVES: To compare health care utilizations between patients who switched
from a branded proton pump inhibitor (PPI) to a generic PPI and vice versa.
METHODS:We conducted a retrospective database analysis using commercial en-
rollees froma largeUShealth plan fromFebruary 2008 toMarch 2010. Continuously
eligible adult patients who had gastroesophageal reflux disease (GERD) or GERD-
related conditions, and evidence of PPI use during February 2009 to September 2009
were included. The index PPI was defined as the first PPI prescribed during the
identification period. Patients who switched from a generic PPI to a branded index
PPI and patientswho switched froma branded index PPI to a generic index PPIwere
included as the two cohorts in this study. Risk adjustment was performed using
propensity score matching. We controlled for age, gender, region, GERD severity,
plan, pre-index Quan-Charlson comorbidity score (CCI), baseline DACON, and
baseline costs and utilization. RESULTS: A total of 9881 patients from each cohort
were matched after propensity score matching. During the six months after the
switch, therewere no significant differences in office visits, emergency roomvisits,
and inpatients admission rates between the two groups of switchers. Patients who
switched from a branded PPI to a generic PPI had a slightly lower rate of outpatient
visits compared to patients who switched from a generic PPI to a branded PPI
(54.67% vs. 56.23%, p0.0275). CONCLUSIONS:Although outpatient visit rates were
slightly lower for patientswho switched froma branded to a generic PPI, therewere
no significant differences in other health care utilizations such as office visits,
emergency room visits, and inpatient admissions.
Gastrointestinal Disorders – Cost Studies
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THE ECONOMIC BURDEN OF ADVANCED LIVER DISEASE AMONG PATIENTS
WITH HEPATITIS C VIRUS: A STATE MEDICAID PERSPECTIVE
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OBJECTIVES: Untreated chronic hepatitis C (HCV) may progress to advanced liver
disease (ALD), including decompensated cirrhosis (DC) and/or hepatocellular car-
cinoma (HCC). ALD can lead to significant clinical and economic consequences,
including liver transplantation. There are limited data on ALD-associated health-
care costs among HCV-infected patients in a Medicaid program.METHODS: Using
Florida Medicaid administrative claims data, we identified cases with HCV diagno-
sis on an inpatient or outpatient claim, or prescription HCV therapy, with an inci-
dent ALD-related diagnosis (“index event”) between 7/1/1999 and 6/30/2007. ALD-
related conditions included DC, HCC, or liver transplant procedure or history.
Patients were included if they had11months continuousMedicaid eligibility pre-
and post-index, and no enrollment in Medicare or an HMO. A one-to-one matched
control cohort of HCV cases without ALD was generated using age, sex, and race.
2009 USD per-patient-per-month (PPPM) costs were reported and compared be-
tween cases and controls usingWilcoxon rank sum tests. RESULTS: The final study
group included 1,193 cases and 1,193 matched controls (mean age: 49 years; 45%
female; 54% white, 23% black, 23% other). The majority of ALD-related diagnoses
were DC (92%), followed by HCC (6%) and liver transplant (2%). Cases with ALD had
greater comorbidity (mean Charlson score: 3.1 vs. 2.3 among controls, P.001).
All-cause inpatient resource use in the one year follow-up from incident ALD di-
agnosis was significantly greater among cases than controls (74% vs. 27%, P.001).
Mean all-cause PPPM costs (including inpatient, outpatient, pharmacy, and others)
were 3 times greater among cases with ALD than controls ($4,937 vs $1,730,
P.001). CONCLUSIONS: HCV patients with ALD had a 2.9-fold higher economic
burden in Florida Medicaid from 7/99 to 6/07 than the controls in the first year
following ALD development. Preventing or delaying ALD onset in HCV patients
could potentially help reduce this economic burden. Further study is necessary.
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OBJECTIVES: Gastroesophogeal reflux disease (GERD) is a common disease affect-
ing 10-20% of the US adult population. The objective of this study was to estimate
the prevalence of refractory GERD and associated direct medical costs using real-
world data.METHODS: Adult patients with GERD initiating a GERDmedication were
identified using theMarketScan Research Databases (2004-2009) and evaluated in the
twelve months before and after GERD medication initiation. Refractory GERD was
evaluated using an eight point scalewhere one pointwas given for each of the follow-
ing: doubling GERD medication dose (including BID), adding another GERD medica-
tion, switchingGERDmedications, GERD-related procedure receipt, GERD-related sur-
gery receipt, excess GI-related outpatient visits (2), excess GERD-related office visits
(2), or GI-related ER visits. Patients were determined to have refractory GERD if they
had 2 or more points. Annual unadjusted and multivariate adjusted GERD-related
costs (i.e., claims with a GERD diagnosis) and all-cause costs were reported in 2009
dollars for patients with and without refractory GERD. RESULTS: A total of 135,139
GERD patientswere analyzed (mean age 52.9 (SD14.5) years, 44%male). Approx-
imately one-third (31%) of patients had refractory GERD. Versus patients with non-
refractory GERD, refractory GERD patients were more likely to be female (59% vs.
55%, p0.001) and had a higher Deyo Charlson Comorbidity score after GERDmed-
ication initiation (0.78 vs. 0.56, p 0.001); average age was similar in both groups.
Compared to non-refractory GERD patients, refractory GERD patients had higher
total all-cause costs ($18,088 (SD$36,220) versus $11,044 ($22,985), p0.001) and
higher GERD-related costs ($2,022 (SD$2,236) versus $1,172 (SD$1,117), p0.001).
After controlling for demographic and clinical characteristics, refractory GERDwas
associated with an additional $7,089 (SD$7,705) in total costs and $845 (SD$111)
in GERD-related costs. CONCLUSIONS: Refractory GERD is a common disease that
may be associatedwith increasedmedical resource utilization and associated cost.
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OBJECTIVES: Inflammatory bowel disease (IBD) affects 1-1.4 million people in the
United States. IBD affects people during their economically productive adult lives
and can have potential economic impact of IBD on productivity loss in the work-
force.We compared risk, absenteeism, andmedical/pharmacy costs for employees
with IBD and fivemost prevalent chronic conditions.METHODS:Health-risk infor-
mation and self-reported illness days using health-risk assessment (HRA) data
were examined and direct Healthcare costs (medical and pharmacy) using claims
data for employees, retirees, and their adult dependents of a large self-insured
employer were compared from 2002-2006 among individuals with IBD and five
most prevalent chronic conditions; asthma, coronary artery disease/congestive
heart failure (CAD/CHF), diabetes, hypertension, chronic obstructive pulmonary
disease (COPD). RESULTS: 44 individuals with IBD were identified. The IBD cohort
had moderate health-risk score (2.6/5) which was comparable to individuals with
asthma (2.8/5), CHF (2.9), hypertension (2.6) and lower than diabetes (3.2/5) and
COPD (3.4/5). Whereas, higher proportion (31.8%) of individuals with IBD had 5
illness days per year as compared with individuals with asthma (31.8%), CAD/CHF
(25.9%), hypertension (20.4%), diabetes (28.4%), and COPD (33%). Annual direct
healthcare costs were higher for individuals with IBD ($24,911) as compared to
individuals CAD/CHF ($22,916), and hypertension ($18,632), and lower as compared
to individuals with asthma ($25,814), diabetes ($28,035), and COPD ($38,839).
CONCLUSIONS: Individuals with IBD have similar health-risks but higher illness
days, and direct healthcare costs as compared to the individuals with five most
prevalent chronic conditions. IBD is a high costs and lost productivity driver for
employers. Population health based programs that engage employees in appropri-
ately managing their chronic conditions can help employers reduce health-risks,
improve productivity, and may help reduce healthcare costs as well.
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OBJECTIVES: To compare the direct medical costs and services by point of service
(PoS) and the prescription drug (Rx) costs and services for persons with Hepatitis-C
(HCV) who are treated (HCV-Tx) and not-treated (HCV-noTx). METHODS: A retro-
spective analysis using the HCMS Research Reference database, which represents
multiple US-based employers and contains employee data from 2001-2Q2007. This
analysis compared the annual direct medical costs and services for healthcare by
PoS, and Rx costs and services for HCV employees with and without Tx. ICD-9
Codes were used to identify employees with HCV. All subjects were required to
have1 month of eligibility. The first ribavirin, interferon or peginterferon Rx was
the HCV-Tx cohort’s index date. The HCV-noTx cohort was assigned the average
index date (by company) of the HCV-Tx cohort. Two-part regression models were
used to compare the cohorts adjusting for demographics, job-related variables,
eligibilitymonths, and Charlson Comorbidity Index. PoS Locations include: doctors
office (MD), inpatient hospital (IN), outpatient hospital or clinic (OUT), emergency
department (ED), laboratory (LAB), and other. Annual Rx costs and services were
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also calculated. All costs were inflated to 2010 US$. RESULTS: Data were available
for 900 employees (HCV-Tx216;HCV-noTx684). The cohorts differed in salaries,
the %married, %white, and %exempt. Mean HCV-noTx cohort IN ($836,P0.0001)
and OUT ($488,P0.0018) costs were higher, and HCV-Tx MD ($564, P0.0001), LAB
($42,P0.0001) and Rx ($21,420,P0.0001) costs were higher. The HCV-noTx cohort
had more IN services (1.83, P0.0021), while the HCV-Tx cohort had more MD
(15.48,P0.0001), LAB (3.31,P0.0001) and Rx (12.0,P0.0001) services. Overall,
HCV-Tx direct medical costs were $3556 (services54.40) which were lower than
the HCV-noTx ($4234;services35.39). The HCV-Tx cohort had 27.84 Rxs ($22,726)
vs the HCV-noTx cohort’s 15.84 Rxs ($1408). CONCLUSIONS: Higher costs associ-
ated with HCV Treatment in the MD office offset IN and OUT costs.
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OBJECTIVES: To determine if subsets of gastroesophageal reflux disease (GERD)
patients vary with respect to healthcare utilization.METHODS: This retrospective
analysis identified commercial enrollees 18-75 years oldwith claims for GERD (ICD-
9-CM: 530.81 or 530.11) and proton pump inhibitors (PPI) during 01/01/05 – 06/30/09.
Patients were further required to have no claims for HIV, pregnancy, inflammatory
bowel disease or cancer at any time, or GERD prescription or gastric/duodenal ulcer
prior to initial GERD diagnosis. Eligible patients were then stratified based onmed-
ical claims for other symptoms during a 12 month period centered on their first
GERD diagnosis: Stage A (GERD diagnosis, no other symptoms); Stage B (GERD 
respiratory symptoms); Stage C (GERD  Barrett’s esophagus); Stage D (GERD 
esophageal stricture); Stage E (GERD  iron deficiency anemia or acute hemor-
rhage). The stages were compared with respect to GERD treatment, other gastro-
intestinal symptoms and GERD-related or all-cause costs for outpatient, inpatient,
and pharmacy care during the first six months after initial diagnosis using univar-
iate statistics.RESULTS: 174,597 patientswere analyzed: StageA: 74%, Stage B: 20%,
Stage C: 1%, Stage D: 2%, Stage E: 3%. Versus stages A and B, patients in Stages C-E
were more likely to visit a gastroenterologist (53.9% vs. 12.9%), receive multiple PPI
(11.5% vs. 7.4%) and had higher rates of gastritis/duodenitis (17.0% vs. 5.9%), esoph-
ageal ulcers (4.4% vs. 0.3%), and esophageal surgery (7.6% vs. 0.3%). Six month
GERD-related costs ranged from $615/patient (Stage A) to $1,714/patient (Stage D);
all-cause costs ranged from $4,195/patient (Stage A) to $11,340/patient (Stage E)
(p0.0001 for all contrasts). CONCLUSIONS: While GERD patients with additional
complications represented a relatively small portion of the total sample, their signif-
icantly higher costs and events suggest an opportunity for improving patient care.
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THE ECONOMIC AND QUALITY OF LIFE BURDEN OF ILLNESS IN CHRONIC
CONSTIPATION (CC) AND IRRITABLE BOWEL SYNDROME (IBS): A SYSTEMATIC
REVIEW
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OBJECTIVES: To systematically review literature on the burden of illness in pa-
tients with CC and IBS subtypes.METHODS:Medline, Medline In-process, EconLit,
CINAHL, Cochrane Library, and AGA abstracts were searched. Studies reporting
economic and quality of life (QOL) outcomes in IBS or CC patients were included.
Study designs included case control, observational studies, surveys, and retrospec-
tive analyses. RCT and studies reporting outcomes attributable to a specific therapy
were excluded. RESULTS: 882 unique studies were identified and 35 selected: 16
evaluated economicmeasures only, 16 humanisticmeasures only, and 3 economic
and humanistic measures. Studies were excluded if patient populations or out-
comes were not relevant. Selected studies included a total of 63,816 patients: 1,706
IBS-C, 2,264 IBS-D, 2,892 IBS-A, 15,830 IBS sub-type unspecified, and 1,278 CC pa-
tients. Nineteen studies assessed economic measures: 11 evaluated direct costs, 1
indirect costs, and 7 direct and indirect costs. Indirect costs generally reflected
estimated work productivity loss due to IBS symptoms or healthcare-seeking be-
havior. US-based estimates of direct costs per IBS patient were $1,562/year (2002
USD) to $7,547/year (year NR, published in 2000); direct costs per CC patient were
$1,912/year (2002USD) to $7,522/year (2002-2003USD). Indirect per IBS patient costs
ranged from $791/year (1998 USD) to $7,737/year (year NR, published 2005). No
study assessed costs associated with IBS-C/D/A subtypes. In studies comparing IBS
patients to non-IBS controls, IBS patients had significantly lower SF-36 domain scores,
notably in vitality, general health, and physical functioning. CONCLUSIONS: Our re-
search identified a range ofmethods and estimates of the burden of IBS and CC. No
economic study reported recent cost estimates by IBS subtypes; only two estimated
direct costs of CC. No studies presented QOL information in CC patients; however,
patients suffering from IBS hadmeasurable burden of disease based onQOL scores.
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DOSE VARIATIONS WITH ADALIMUMAB AND INFLIXIMAB IN THE TREATMENT
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OBJECTIVES: In Canada, adalimumab and infliximab are approved for the treat-
ment of moderate to severe active Crohn’s disease (CD). Product monographs sug-
gest that the dose may be increased in case of incomplete response. The objective
of this study was to analyze, in a real world setting, dose variations in CD patients
who initiated adalimumab or infliximab treatment. METHODS: A retrospective
cohort study was conducted using data from the Regie de l’assurance maladie du
Quebec (RAMQ) for a random sample of patients with a CD diagnosis, who had
initiated adalimumab or infliximab between February 2008 andDecember 2008. For
adalimumab, dose increase was considered when the dose received exceeded
40mg every otherweek over at least an 8-week period. For infliximab, dose increase
was considered either when the dose was increased or interval between doses was
reduced for two periods of 8 weeks after the third injection. RESULTS: The cohort
included a total of 290 patients of which 135 patients were initiatedwith infliximab
and 155 with adalimumab. The mean age was 42.2 years (SD16.9). After 12
months, 14.2%(22/155) of patients with adalimumab and 22.2%(30/135) of patients
with infliximab had experienced a dose increase (p0.05). Average medication
costs in the year following initiation of adalimumab or infliximab, for patients who
did not adjust doses were CAD$10,250 and CAD$14,957, respectively (p0.01). For
patients who experienced a dose increase or reduced interval between doses, av-
erage medication costs were CAD$19,789 with adalimumab and CAD$25,550 with
infliximab (p0.013). CONCLUSIONS: CD patients treated with infliximab had a
significantly higher rate of dose increases compared with patients treated with
adalimumab. Results of this RAMQdatabase analysis illustrate that, in a real-world
setting, dose increase or reduction of interval between doses are associated with
increased treatment costs. In both recommended and adjusted dosing, adali-
mumab demonstrated significant cost savings over infliximab.
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OBJECTIVES: To assess the economic value of treating CHB patients with Entecavir
relative to the current situation in Russiawith no treatment.METHODS:Wecarried
out the Perceived Value Assessment (PVA) of Entecavir (937 patients) vs. no treat-
ment (971 patients) using amultilayeredMarkovianmodel (disease state transition
model: F0/F1 – F2/F3/F4 (Fibrosis) –F4 (Advanced Fibrosis/Cirrhosis) – Decompen-
sated Cirrhosis – Hepatocellular Carcinoma – Liver Transplant – Post Liver Trans-
plant), developed by J.Wells fromMonitor Group. It is consistentwith a cost-benefit
analysis, where the clinical benefits of treatment with ETV (occurrence of histolog-
ical improvement and CHB disease regression, avoidance of renal adverse events,
avoidance of additional monitoring requirements) are expressed in monetary
terms (Rubles). Costs of treating a chronic Hepatitis B patient per day avoided by 5
years of Entecavir treatment and 25 years of follow up (total 30 years) can be
considered as benefits of treating. RESULTS: As patients progress into more ad-
vanced disease states their treatment becomes disproportionately more expen-
sive: 420.7 USD for F0/F1, 1 935.2 USD for F2/F3/F4, 2 515.6 USD forF4, 10 947.1 USD
for Decompensated Cirrhosis, 4 549.9 USD for Hepatocellular Carcinoma, 10 092
USD for Liver Transplant, 49 613.6 USD for Post Liver Transplant. Costs of treating
a CHB patient avoided by 5 years of Entecavir treatment and 25 years of follow up –
30.3 USD per day: 4.8 USD per day for F0/F1, F2/F3/F4 and F4; 3.2 USD per day for
Decompensated Cirrhosis; 0.6 USD per day for Hepatocellular Carcinoma; 0.45 USD
per day for Liver Transplant; 21.25 USD per day for Post Liver Transplant. Cost of
Entecavir treatment is 8.8 USD per day (29.1 % of total costs avoided per patient per
day of Entecavir treatment). CONCLUSIONS: Entecavir represents a true “spend to
save” strategy: cost of therapy is fully outweighed by the economic benefits of
treatment.
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OBJECTIVES:Chronic hepatitis B (CHB) can lead to progressive liver disease, including
cirrhosis, hepatocellular carcinoma and death. New options for long-term antiviral
treatment decrease financial burden of CHB to the healthcare system and require
physicians, payers and healthcare decision-makers to evaluate its economic value.To
assess the economic value of treatment with Entecavir relative to treatment with
Tenofovir in the Russian healthcare system.METHODS:We carried out the Perceived
Value Assessment (PVA) of Entecavir (ETV) vs. Tenofovir (TFV) using multilayered
Markovian model (disease state transition model: F0/F1 – F2/F3/F4 (Fibrosis) – F4
(Advanced Fibrosis/Cirrhosis) – DecompensatedCirrhosis –Hepatocellular Carcinoma
– Liver Transplant – Post Liver Transplant), developed by J.Wells fromMonitor Group.
In termsof PVAmodelweevaluated thecomparativevalueprovided to thehealth care
systembyEntecavir versusTenofovir treatment (total of 30 yearsmodeled) depending
on duration of treatment and the follow-up period. The primary outcomemeasure of
the model is the “Per pill Cost”. RESULTS: As patients progress into more advanced
disease states their treatment becomesdisproportionatelymore expensive: 420.7USD
for F0/F1, 1 935.2 USD for F2/F3/F4, 2 515.6 USD for F4, 10 947.1 USD for Decompen-
sated Cirrhosis, 4 549.9 USD forHepatocellular Carcinoma, 10 092USD for Liver Trans-
plant, 49 613.6USD for Post LiverTransplant. ETV’sprice is only 0.11 greater thanTFV’s
price. Value gapbetweenETVandTFV for 5 years of therapywith 25 years of follow-up
period was 4.8 USD per pill. It was determined by the long-term efficacy of ETV.
CONCLUSIONS: PVA Cost benefit simulation with 30 year time horizon and maxi-
mum treatment duration of 5 years demonstrated ETV’s economic valuewas 4.8 USD
greater than that of TFV.
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